Protalix Biotherapeutics Inc
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also dev… Read more
Protalix Biotherapeutics Inc (PLX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.071x
Based on the latest financial reports, Protalix Biotherapeutics Inc (PLX) has a cash flow conversion efficiency ratio of -0.071x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.73 Million) by net assets ($52.91 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Protalix Biotherapeutics Inc - Cash Flow Conversion Efficiency Trend (1996–2024)
This chart illustrates how Protalix Biotherapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Protalix Biotherapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Protalix Biotherapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
METALS EXPLOR. LS 00001
F:MJ4
|
N/A |
|
Profit Cultural & Creative Group Co Ltd
SHE:300640
|
-0.018x |
|
Zhejiang Shapuaisi Pharmaceutical Co Ltd
SHG:603168
|
0.005x |
|
Gansu Guofang Gongmao(Grp)
SHG:601086
|
0.031x |
|
Freegold Ventures Limited
OTCQX:FGOVF
|
0.000x |
|
ON24 Inc
NYSE:ONTF
|
0.018x |
|
Sinpas Gayrimenkul Yatirim Ortakligi AS
IS:SNGYO
|
-0.005x |
|
Zhejiang Jinsheng New Materials Co
SHE:300849
|
0.040x |
Annual Cash Flow Conversion Efficiency for Protalix Biotherapeutics Inc (1996–2024)
The table below shows the annual cash flow conversion efficiency of Protalix Biotherapeutics Inc from 1996 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $43.21 Million | $8.67 Million | 0.201x | +611.27% |
| 2023-12-31 | $33.57 Million | $-1.32 Million | -0.039x | -101.67% |
| 2022-12-31 | $-10.64 Million | $-25.00 Million | 2.350x | +37.89% |
| 2021-12-31 | $-6.04 Million | $-10.29 Million | 1.704x | +76.47% |
| 2020-12-31 | $-27.04 Million | $-26.11 Million | 0.966x | +250.76% |
| 2019-12-31 | $-70.32 Million | $-19.36 Million | 0.275x | +88.03% |
| 2018-12-31 | $-52.88 Million | $-7.74 Million | 0.146x | -54.16% |
| 2017-12-31 | $-31.29 Million | $-9.99 Million | 0.319x | -90.09% |
| 2016-12-31 | $-9.96 Million | $-32.10 Million | 3.224x | +244.34% |
| 2015-12-31 | $10.87 Million | $-24.28 Million | -2.233x | -524.10% |
| 2014-12-31 | $-55.60 Million | $-29.28 Million | 0.527x | -53.71% |
| 2013-12-31 | $-26.95 Million | $-30.65 Million | 1.138x | +701.39% |
| 2012-12-31 | $-3.36 Million | $635.00K | -0.189x | -120.93% |
| 2011-12-31 | $-26.08 Million | $-23.57 Million | 0.904x | -73.39% |
| 2010-12-31 | $-11.32 Million | $-38.46 Million | 3.397x | +21.38% |
| 2009-12-31 | $15.88 Million | $44.45 Million | 2.799x | +874.99% |
| 2008-12-31 | $44.35 Million | $-16.02 Million | -0.361x | -120.10% |
| 2007-12-31 | $63.69 Million | $-10.45 Million | -0.164x | +21.74% |
| 2006-12-31 | $24.28 Million | $-5.09 Million | -0.210x | -164.51% |
| 2005-12-31 | $914.43K | $-72.47K | -0.079x | +76.65% |
| 2004-12-31 | $495.36K | $-168.12K | -0.339x | -62.75% |
| 2003-12-31 | $655.43K | $-136.68K | -0.209x | -13.26% |
| 2002-12-31 | $796.15K | $-146.59K | -0.184x | +77.94% |
| 2001-12-31 | $945.91K | $-789.43K | -0.835x | -2011.77% |
| 2000-12-31 | $1.34 Million | $-53.11K | -0.040x | +95.54% |
| 1999-12-31 | $1.59 Million | $-1.41 Million | -0.886x | -226.92% |
| 1998-12-31 | $3.35 Million | $-909.52K | -0.271x | -- |
| 1997-12-31 | $0.00 | $-247.92K | x | -- |
| 1996-12-31 | $0.00 | $-40.57K | x | -- |